KLRC1 and acute myeloid leukemia: For the mature NK subset, we noticed a homogenous behavior among all investigated inhibitory molecules in the MDS cases, showing consistent lower percentages of NK cells expressing CD159a or KIRs (P = 0.0102), while the AML cases displayed a high heterogeneity, P = 0.8250 (Figures 5B–D, and Supplementary Figure 5B).